Aerial BioPharma, LLC

Licensing deals involving drugs for central nervous system conditions were worth more in 2016 than previous years, although there are fewer agreements being signed in this disease space. One of the mo

Jazz Pharmaceuticals PLC 'srelease ofpositive data for its JZP-110 in two Phase III studies boosts prospects for the drug, keeping it on track for a filing in obstructive sleep apnea and narcolepsy i

Four venture capital firms have raised more than $1bn in new money for life science and health care investments, which could be divided among a large number of biotechnology companies if a recent tren

Biopharma start-ups continued the active pace of dealmaking in 2014, which featured a notable bump in partnerships for infectious disease programs, as well as some structured agreements built with opt